Marco Meglio

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Lindsay McCullough, MD. [LISTEN TIME: 14 minutes]

The director of the Pediatric Epilepsy Center at UCSF reviewed recently presented interim phase 1/2 data for ETX101, a one-time AAV9 gene regulation therapy aiming to increase SCN1A expression in inhibitory interneurons in Dravet syndrome.

Explore the transformative buzzwords in neurology for 2025, highlighting advancements in AI, gene therapy, personalized treatment, and neuroplasticity.

Gain Therapeutics advances Parkinson's treatment with GT 2287, showcasing promising safety and tolerability in ongoing trials. Discover the latest findings.

Continuem's PIPE-307 trial for relapsing-remitting multiple sclerosis failed to meet primary goals, yet the company remains committed to exploring future therapies.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on neuromodulation for Parkinson disease!

New findings from the LUMINA trial reveal AMX0114's safety in ALS patients, paving the way for further research and potential treatment advancements.

GLP-1 research in neurology is on the rise, with several pivotal studies lending insights into their role.

Phase 3b study revealed Itvisma's safety and efficacy in treating spinal muscular atrophy, showing modest motor function improvements in patients previously on other therapies.

Angela Lek, PhD, chief research officer of the Muscular Dystrophy Association, discusses the FDA approval of intrathecal onasemnogene abeparvovec (Itvisma; Novartis) and what it means for SMA treatment across older pediatric and adult populations.

Elizabeth Gerard, MD, an epileptologist at Northwestern Medicine, provided clinical insights on a new consortium, GEAN, which aims to expand genetic testing and define adult phenotypes for rare genetic epilepsies across North America.

Christopher Kenney, MD, FAAN, chief medical officer at Xenon Pharmaceuticals, reviews encouraging long-term data behind azetukalner, a first-in-class Kv7 channel opener, as a potential treatment for focal onset seizures.

Sanofi's tolebrutinib fails to meet key trial endpoints for multiple sclerosis, delaying FDA review and raising questions about its future in treatment.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on FcRn-blocking therapies in neurology!

Elizabeth Thiele, MD, PhD, director of the Pediatric Epilepsy Program at Massachusetts General Hospital, discusses new data on Epidiolex use in DEEs beyond Dravet, LGS, and TSC.

The director of the Adult Epilepsy Genetics Clinic at Northwestern University discussed short- and long-term goals for research, natural history development, and community engagement of the AES-sponsored GEAN Consortium. [WATCH TIME: 3 minutes]

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Sneha Mantri, MD, MS. [LISTEN TIME: 24 minutes]

New findings reveal bexicaserin significantly reduces seizure frequency in patients with developmental and epileptic encephalopathies, supporting its advancement to phase 3 trials.

The neurosurgeon at Cleveland Clinic discussed the goals of the AES thalamic neuromodulation special interest group and the major clinical and research priorities shaping the future of neuromodulation for drug resistant epilepsy.

The positive interim findings research represents the first clinical data for ETX101, an investigational cell-type-selective gene therapy, and the first potential one-time disease-modifying treatment for Dravet syndrome.

The director of the Pediatric Epilepsy Center of Excellence at the University of California San Francisco detailed early phase data of Encoded Therapeutics’ ETX101 gene replacement therapy in children with Dravet syndrome. [WATCH TIME: 3 minutes]

Sharon Hesterlee, PhD, president and CEO of the Muscular Dystrophy Association, discussed the 2026 MDA Conference, the significance of its keynote speaker, and the evolving therapeutic landscape in neuromuscular medicine.

Ovid Therapeutics' OV329 shows promise as a safe, effective GABA-AT inhibitor for treating drug-resistant seizures, with strong phase 1 trial results.

New AES 2025 data reinforce zorevunersen’s disease-modifying potential in Dravet syndrome, showing durable seizure reduction, functional improvements, and a consistent safety profile.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on autonomic dysfunction in long COVID!

Recent analysis reveals Epidiolex significantly reduces seizures in patients with various developmental epileptic encephalopathies, showcasing its broad effectiveness.

A study reveals EEG and MRI biomarkers in MOGAD patients with epilepsy, highlighting potential early indicators for refractory epilepsy and improved treatment outcomes.

New findings reveal the challenges of treating pediatric epileptic encephalopathy with NBI-827104, highlighting the need for effective therapies.

New STIRUS data unveiled at AES 2025 demonstrate meaningful real-world reductions in seizures, status epilepticus, and healthcare needs with stiripentol in Dravet syndrome.

A groundbreaking phase 1 trial reveals promising results for a new stem cell therapy targeting Alzheimer disease, advancing to phase 2 studies.